Athyrium Capital Management, LP Puma Biotechnology, Inc. Transaction History
Athyrium Capital Management, LP
- $4.1 Million
- Q2 2024
A detailed history of Athyrium Capital Management, LP transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Athyrium Capital Management, LP holds 1,256,411 shares of PBYI stock, worth $3.24 Million. This represents 100.0% of its overall portfolio holdings.
Number of Shares
1,256,411
Previous 1,256,411
-0.0%
Holding current value
$3.24 Million
Previous $6.66 Million
38.5%
% of portfolio
100.0%
Previous 100.0%
Shares
4 transactions
Others Institutions Holding PBYI
# of Institutions
98Shares Held
30.5MCall Options Held
73.5KPut Options Held
18.5K-
Vanguard Group Inc Valley Forge, PA3.6MShares$9.29 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.57MShares$9.22 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.16MShares$8.16 Million0.0% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.06MShares$7.9 Million0.59% of portfolio
-
Acadian Asset Management LLC Boston, MA1.95MShares$5.03 Million0.02% of portfolio
About PUMA BIOTECHNOLOGY, INC.
- Ticker PBYI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,556,000
- Market Cap $118M
- Description
- Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...